Inhalon Biopharma
Carrboro
About Inhalon Biopharma
Inhalon Biopharma is into developing monoclonal antibodies (mAb) using technology that enables trapping of pathogens in mucus secretions for treating diseases of the respiratory tract.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $11.9M
- Funding stage: Seed
- Last round: Grant (Nov 2022)
- Website: inhalon.com
- Phone: 607-279-1880
Industries & Categories
Biopharma, Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/inhalon-biopharma-69859 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.